Expired activity

Please go to the PowerPak homepage and select a course.

Faculty

Rebecca J. Nelson, PharmD, BCOP
Clinical Pharmacy Coordinator, Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Program Description

Participants in this enduring educational activity will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Participants will understand how to differentiate between the novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors. Additionally, there will be discussion on strategies to optimize patient satisfaction and communication by addressing clinical challenges, promotion of patient adherence, proper management of adverse events, and the encouragement of open communication between provider and patient.

Intended Audience

This activity is designed to meet the educational needs of hospital and health-system pharmacists, pharmacy directors, and pharmacy residents.

Educational Objectives

Upon completion of this educational activity, participants will be able to:

• Discuss the molecular pathophysiology associated with the development of CLL, the role of the B-cell receptor (BCR) pathway, and the rationale for therapeutically targeting this pathway.
• Appraise recent clinical safety and efficacy data in novel CLL therapies for use in both monotherapy and combination, focusing on differentiating factors seen among the various agents.
• Assess the latest clinical CLL guideline recommendations for selection and sequencing of therapy, individualized to the patient, including mutation status, performance status, comorbidities, and patient preferences.
• Using a case-based approach, explore the various clinical challenges pharmacists face with the use of CLL novel therapies in practice, including preventing and managing toxicities, promoting patient adherence, and fostering a team-based environment to improve patient care. and appropriately manage adverse events, and answer challenging clinical issues pharmacists may encounter in their practice.

ACCREDITATION STATEMENTS

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This enduring activity is approved for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-21-013-H01-P).
Creative Educational Concepts, Inc. certifies this activity for 1.0 hours of participation.

Disclosure of Conflicts of Interest Policy

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving support from commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Disclosure of Unlabeled Use

This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA) or are currently investigational.

Disclaimer

It is the policy of CEC to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.

Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC for any product or manufacturer identified.

Planner

Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters

Rebecca J. Nelson, PharmD, BCOP—has disclosed that she is on the speakers’ bureau for AbbVie, Amgen, BTG Inc., Stemline, and TG Therapeutics.

Peer Reviewer

Alison Duffy, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.

How to Earn Credit

Participants must 1) read the learning objectives and faculty disclosures; 2) complete the pre-assessment questions; 3) view the educational activity in its entirety; and 4) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest. You will have 3 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

Privacy Policy

CEC privacy policy  https://www.ceconcepts.com/sites/default/files/CEC%20Privacy%20Policy_2.pdf